Harrow Q1 Earnings Call Highlights

Harrow (NASDAQ:HROW) executives said the company’s first-quarter results were weighed down by a discrete gross contented tied to VEVYE sum and high-deductible patients, but absorption repeatedly emphasized that underlying request for its halfway ophthalmic products is accelerating.

On the company’s first-quarter 2026 net call, CEO Mark L. Baum said the quarter’s header gross fig reflected “a circumstantial isolated dynamic” alternatively than a deterioration successful demand. Harrow reported consolidated gross of $44.2 cardinal and adjusted EBITDA of antagonistic $12.7 cardinal for the quarter, according to President and Chief Financial Officer Andrew Boll.

→ Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum

“The underlying fundamentals of Harrow person ne'er been stronger,” Baum said, adding that request for the company’s cardinal maturation drivers is “at oregon above” interior expectations.

VEVYE Revenue Hit by Gross-to-Net Issue

Management said VEVYE generated astir $20.9 cardinal successful first-quarter revenue, but that reported gross was reduced by astir $8 cardinal owed to a gross-to-net modeling contented related to expanded commercialized sum that began Jan. 1.

→ 3 Ways to Target the Resources Powering AI and Data Centers

Boll said Harrow’s archetypal concern rules assumed a definite diligent premix and level of out-of-pocket support. While January results tracked with expectations, the institution aboriginal saw a importantly higher proportionality of high-deductible patients filling prescriptions done pharmacy benefits, expanding mean out-of-pocket buydowns and pressuring nett gross per unit.

“Due to the modular manufacture lag successful claims reporting, the afloat magnitude of this premix displacement was confirmed successful mid-April,” Boll said. He said Harrow past implemented targeted changes, including strict caps connected co-pay buydowns and different refinements intended to support nett pricing.